Risk management options elected by women after testing positive for a BRCA mutation

Gynecologic Oncology

Volumn 132, Issue 2, 2014, Pages 428-433

  Garcia, Christine ^a   Wendt, Jacqueline ^a   Lyon, Liisa ^a   Jones, Jennifer ^a   Littell, Ramey D ^a   Armstrong, Mary Anne ^a   Raine Bennett, Tina ^a   Powell, C Bethan ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

BRCA; Breast cancer; Ovarian cancer; Prevention

Indexed keywords

BRCA; BREAST CANCER; OVARIAN CANCER; PREVENTION;

ADULT; BREAST NEOPLASMS; CHEMOPREVENTION; COHORT STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GUIDELINE ADHERENCE; HORMONE REPLACEMENT THERAPY; HUMANS; LOGISTIC MODELS; MASTECTOMY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; RISK FACTORS; RISK MANAGEMENT;

EID: 84894075492     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.12.014     Document Type: Article

References (21)

1. NCCN guidelines for detection, prevention, and risk reduction: genetic/familial high risk assessment: breast and ovarian (v 2.2013). Cancer guidelines http://www.nccn.com/cancer-guidelines.html
2. ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome Obstet Gynecol 113 2009 957 966
3. S.M. Domchek, T.M. Friebel, S.L. Neuhausen, T. Wagner, G. Evans, and C. Isaacs et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study Lancet Oncol 7 3 2006 223 229
4. S.M. Domchek, T.M. Friebel, C.F. Singer, D.G. Evans, H.T. Lynch, and C. Isaacs et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality JAMA 304 9 2010 967 975
5. M.S. Beattie, B. Crawford, F. Lin, E. Vittinghoff, and J. Ziegler Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers Genet Test Mol Biomarkers 13 2009 51 56
6. G.N. Mannis, J.E. Fehniger, J.S. Creasman, V.L. Jacoby, and M.S. Beattie Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing JAMA Intern Med 173 2 2013 96 103
7. T.M. Friebel, S.M. Domchek, S.L. Neuhausen, T. Wagner, D.G. Evans, and C. Isaacs et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers Clin Breast Cancer 7 11 2007 875 882
8. N.D. Kauff, S.M. Domchek, T.M. Friebel, M.E. Robson, J. Lee, and J.E. Garber et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study J Clin Oncol 26 8 2008 1331 1337
9. M.D. Schwartz, C. Isaacs, and K.D. Graves et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance Cancer 118 2012 510 517
10. K. Rhiem, D. Foth, B. Wappenschmidt, H. Gevensleben, R. Büttner, and U. Ulrich et al. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers Arch Gynecol Obstet 283 2011 623 627
11. K.A. Metcalfe, J. Lubinski, P. Ghadirian, H. Lynch, C. Kim-Sing, and E. Friedman et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the hereditary breast cancer clinical study group J Clin Oncol 26 7 2008 1093 1097
12. J.B. Botkin, K.R. Smith, R.T. Croyle, B.J. Baty, J.E. Wylie, and D. Dutson et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing Am J Med Genet 118A 2003 201 209
13. S.T. Tinley, J. Houfek, P. Watson, L. Wenzel, M.B. Clark, and S. Coughlin et al. Screening adherence in BRCA1/2 families is associated with primary physicians' behavior Am J Med Genet 125A 2004 5 11
14. L.J. Loescher, K.H. Lim, O. Leitner, J. Ray, J. D'Souza, and C.M. Armstrong et al. Cancer surveillance behaviors in women presenting for clinical BRCA genetic susceptibility testing Oncol Nurs Forum 36 2 2009 E57 E67
15. M.O. Leach, C.R. Boggis, A.K. Dixon, D.F. Easton, R.A. Eeles, and D.G. Evans et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) Lancet 365 2005 1769 1778
16. S. Dhar, H. Cooper, T. Wang, B. Parks, S.A. Staggs, and S. Hilsenbeck et al. Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers Breast Cancer Res Treat 129 1 2011 221 227
17. R.M. Brohet, D.E. Goldgar, D.F. Easton, A.C. Antoniou, N. Andrieu, and J. Chang-Claude et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group J Clin Oncol 25 25 2007 3831 3836
18. S.A. Narod, M.P. Dube, J. Kiljn, J. Lubinski, H.T. Lynch, and P. Ghadirian et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers J Natl Cancer Inst 94 23 2002 1773 1779
19. V. McGuire, A. Felberg, M. Mills, K.L. Ostrow, R. DiCioccio, and E.M. John et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations Am J Epidemiol 160 7 2004 613 618
20. T. Rebbeck, T. Friebal, Wagner, H.T. Lynch, J.E. Garber, and M.B. Daly et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group J Clin Oncol 23 31 2005 7772 7774
21. A. Eisen, J. Lubinski, Gronwald, P. Moller, H.T. Lynch, and J. Klijn et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers J Natl Cancer Inst 100 19 2008 1341 1343